Jason Brett
Novo Nordisk (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Diabetes Management and Research, Metabolism, Diabetes, and Cancer, Pancreatic function and diabetes, Obesity, Physical Activity, Diet
Most-Cited Works
- → Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)(2009)1,482 cited
- → Evidence Linking Hypoglycemic Events to an Increased Risk of Acute Cardiovascular Events in Patients With Type 2 Diabetes(2011)186 cited
- → Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials(2011)148 cited
- → Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials(2017)109 cited
- → Mild Renal Impairment and the Efficacy and Safety of Liraglutide(2010)79 cited
- → The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States(2019)64 cited
- → Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes ≥65 and <65 Years of Age: A Pooled Analysis from Phase III Studies(2011)62 cited
- → The effect of liraglutide on endothelial function in patients with type 2 diabetes(2014)55 cited
- → Efficacy of Anti Hyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program(2011)49 cited
- → A1c Control in a Primary Care Setting: Self-titrating an Insulin Analog Pre-mix (INITIATEplus Trial)(2009)44 cited